Talwar Newsletter volume Seven

2. NEWSLETTER
Contents
1. Headlines 1
2. News India 2
3. News China 6
4. News Japan 9
5. Editorial 12
TT Consultants is an ISO-27001 and ISO-9001:2008 certified Intellectual Property Consulting
firm providing services in over 20 countries worldwide to more than 500 Companies, universities
and research institutes with several offices in three countries i.e. Taiwan, US and India and strong
client base in US, Canada, Europe, Japan, Singapore, South Korea, Taiwan and India, we strive
towards providing our clients global and world-class services.
We provide patent litigation support, patent prosecution support, licensing support, patent
acquisition support, technology transfer consulting, patent portfolio management and other legal
support services to leading patent law firms, companies, universities, research institutes and
intellectual property owners.

3. INDIA CHINA JAPAN EDITORIAL
HEADLINES INDIA
 India revokes Roche patent in new blow for Big Pharma
 India's Cipla cuts price of 3 more cancer drugs
 India Publishes Draft Guidelines f or Patenting Of TK and Biological Material
 India revokes patent on Merck's asthma drug
 'Amul' loses trademark battle against US giant in court
 ASSOCHAM suggest formation of National IPR Strategy Authority
 India scores lowest on intellectual property protection - index
 Patent laws key to drug innovation, argues report
 American Court rules against confidentiality for Cadila’s ‘in -house’ Indian
counsel
HEADLINES CHINA
 EPO and SIPO launch Chinese-English machine translation for patents
 Global IP Filings Continue to Grow, China Tops Global Patent Filings
 East Asia faces unique challenges, opportunities for stem cell innovation
 China’s new approach to renewable energy
 Light at the end of the tunnel: trademark squatting in China
 China Officially Recognizes Napa Valley Wines
HEADLINES JAPAN
 Japan, China pay a high price
 Japan gives patent for Medgenics IFNa pump
 Astellas-UCB rheumatoid arthritis therapy wins marketing approval in Japan
 Bristol-Myers, Pfizer win approval for Eliquis in Japan
 Novartis future growth prospects secured by industry -leading pipeline
 Roche reports positive studies of MabThera given by subcutaneous injection
 Govt To Mandate Price Cuts On Popular Off -Patent Drugs
EDITORIAL
 The prime solution - Invalidation search
© TT Consultants, 2012. All rights reserved – privileged and confidential

4. NEWS INDIA
India revokes Roche patent in new blow for Big Pharma
The Intellectual Property Appellate Board (IPAB) cited a lack of
evidence that the drug was any better than
Patent Invalidation existing treatments and its high price as
Search reasons for the decision. Pegasys was the first
medicine to win protection in 2006 under
Lupin bags final approval
We ‘scour the earth’ India's new patent regime and the revocation
from USFDA to market
when it comes to will rekindle tensions between New Delhi and
generic contraceptive
searching for prior art global drug makers worried by the country's
tablets
in order to invalidate a tough stance.
troublesome patent. The decision follows another high-profile setback for the industry in
If you use ‘Xerox’ the way
We have helped March, when India granted the first ever compulsory licence to domestic drug
you use ‘zipper,’ our
several US and Asian maker Natco (NATP.NS) to sell cheap copies of Bayer's (BAYGn.DE) cancer
trademark could be left
companies save huge drug Nexavar.
wide open
litigation costs by
Read More>> Go to the top>>
India announced highly
uncovering
Nationalprior arts. We
useful Policy on
have Mandarin,
Electronics 2012; wants to
rival China and Korea
Japanese India's Cipla cuts price of 3 more cancer drugs
native searching Cipla Ltd. -- one of India's largest generic-drug manufacturers--said
AstraZeneca unveils
capability. We are a Thursday it is cutting prices for three cancer medicines it sells in India by up
antiplatelet drug Brilinta
preferred choice for to 63%. Cipla is cutting prices of these cancer drugs to make them "affordable
in India
companies involved in and accessible" for patients, Cipla Chairman Y.K. Hamied said in a statement.
After India, now patent
complex
The price of Erlocip, a generic version of Roche Holding AG
litigation and have
Indonesia introduces
(RHHBY)'s lung-cancer treatment Tarceva, has been reduced by 63% across
Patent Licenses for Joint
represented many various strengths. Now 30 tablets of Erelocip 150 will cost 9,900 rupees
Generic VersionsGroups
Defense of ($181) versus 27,000 rupees earlier. The prices of docetaxel--used in the
Drugs in such cases to
(JDGs) treatment of breast, lung and other cancers--and capecitabine have been
identify relevant prior halved, Cipla added in the statement.
art for invalidating
Read More>> Go to the top>>
potentially dangerous
patents.
India Publishes Draft Guidelines for Patenting Of TK and
Biological Material
The government of India has released a set of draft guidelines to be
followed in the patenting of traditional knowledge and biological material.
Page 2 of 13
© TT Consultants, 2013. All rights reserved – privileged and confidential

5. NEWS INDIA
Comments are due by 22 November. “It has been reported that the Indian
Patent Office is granting patents on the use of traditional knowledge (TK) of
India, particularly relating to the Ayurveda, Unani and Siddha systems of
Patentability Search medicine, etc. and patents have been granted on inventions related to
biological resources obtained from India without taking adequate care to
A thorough patentability observe the mandate of law,” the draft guidelines state.
assessment search conducted
The guidelines mention India’s primary role in a range of international policy
on an exhaustive list of
developments related to TK and genetic resources. Pending patent
patent and non-patent applications involving traditional knowledge are published on.
databases. We offer
innovative search reports Read More>> Go to the top>>
that come along with a key
feature chart and many value
additions offered by none India revokes patent on Merck's asthma drug
other in the industry. This
Indian Patents Office has revoked a patent for an asthma drug held by
service is being extensively US-based Merck & Co following a challenge
used by the best research from domestic pharma firm Cipla. In an order,
institute of Asia, several Assistant Controller of Patents & Designs T V
national universities of Madhusudhan revoked the patent on the
Taiwan, top law firms in the ground that it lacked invention.
US and 5 fortune 500
"The sole process claim also in its
companies to name a few.
entirety is not inventive as the said claim does not describe any inventive
feature," the order said. "In view of the above conclusion I hereby order that
the patent bearing number 246328 is revoked," Madhusudhan said in his
order.
Schering Corporation, which was later acquired by Merck & Co, had
applied for patent of the asthma drug in February 2004, and the Indian Patents
Office had granted the patent in March 2011. Cipla had challenged the patent.
Read More>> Go to the top>>
'Amul' loses trademark battle against US giant in court
The Gujarat High Court has refused to set aside an order which
cancelled Amul's registration of its trademark 'TRIX', on which a US firm has
claimed its right. In July this year, the Intellectual Property Appellate Board
had directed Registrar of Trademarks to cancel Amul's registration of TRIX
trademark.
Page 3 of 13
© TT Consultants, 2013. All rights reserved – privileged and confidential

6. NEWS INDIA
A Division Bench of Chief Justice Bhaskar Bhattacharya and Justice J
B Pardiwala, in a recent judgement, dismissed the petition filed by Kaira
District Cooperative Milk Producers Union Ltd, owner of Amul, seeking
cancellation of trademark 'TRIX' registered in favour of US food giant
General Mills.
Freedom to Operate
Search Read More>> Go to the top>>
We provide a
proactive patent ASSOCHAM suggest formation of National IPR Strategy
study for mitigating
Authority
the risks involved Report by India Education bureau, New Delhi: The Associated
before entering a Chambers of Commerce and Industry of India (ASSOCHAM) has suggested
new jurisdiction and establishment of National Intellectual Property Right (IPR) Strategy Authority
have the capability to Department of Industrial Policy & Promotion (DIPP) in the context of fast
to search in various changing trade environment driven by global competition, innovation risks,
geographies short product life cycle, rapid changes in technology involving huge
including most of investments in Research & Development and human resource.
the Asian countries
The proposed Authority should be aiming of aligning towards
and some European
achieving a target of 50,000 patent applications filed in India in 2015 and 1,
countries. Our 50,000 in 2020. Similar targets should also be set for filing of design and trade
experienced mark applications.
professionals
perform an in-depth Read More>> Go to the top>>
search and very
closely examine the
prior art vis-à-vis the India scores lowest on intellectual property protection - index
product features. The index prepared for the group's Global Intellectual Property Center
Claim charts are scored 11 countries on a point scale from
zero to 25, with the United States receiving
prepared based
the highest overall tally of 23.73 and
upon the national
Britain coming in second at 22.40.
patent laws.
India was last with 6.24 points,
reflecting its low scores in each of the five
categories examined by Pugatch
Consilium, an international research and analysis firm that specializes in the
knowledge economy. China was tenth with a score of 9.13, below Brazil with
9.57 points and Russia with 11.17.
The new index is intended as a tool for U.S. policymakers to push for
tough protections of U.S. copyrights, patents and trade secrets in free trade
Page 4 of 13
© TT Consultants, 2013. All rights reserved – privileged and confidential

7. NEWS INDIA
agreements and other international talks.
The United States, with some of the strongest copyright, patent and
trademark protections in the world, has a total stock of intellectual property
valued at around $5.8 trillion.
Structure Sequence Read More>> Go to the top>>
Search
When you request a Patent laws key to drug innovation, argues report
chemical structure/ Pharmaceutical innovation in middle-income countries such as Brazil
substructure search, and India could be boosted by stronger
our domain specific enforcement of intellectual property laws and by
searchers with building up research capacity, says a report.
extensive experience
The report by global consultancy Charles
perform patent
River Associates has identified the conditions
searches and deliver required to encourage innovation in middle-
insightful results for income countries by evaluating government policies that promote investment
compounds matching in local innovative activities in the biopharmaceutical field.
the query structure,
as well as for Commissioned by the International Federation of Pharmaceutical
compounds Manufacturers & Associations (IFPMA) — an NGO representing the
pharmaceutical, biotechnology and vaccine sectors — the document was
containing the query
released at the 26th IFPMA Assembly last month (31 October).
structure as a subset
(substructure) of a Read More>> Go to the top>>
larger structure.
Page 5 of 13
© TT Consultants, 2013. All rights reserved – privileged and confidential

8. NEWS CHINA
EPO and SIPO launch Chinese-English machine translation
for patents
Breaking new ground in providing access to the most comprehensive
Patent Drafting & technological information, the European
Patent Office (EPO) and the State Intellectual
Illustrations
Property Office of the People's Republic of
A well drafted patent China (SIPO) today launched the Chinese-
is the key to a strong English component of the EPO's free
patent and holds the automatic translation service Patent Translate.
highest chances of As a result, the collections of the two largest languages in patents are
being accepted by the now united as full-text documents on the same website through the EPO's
National Patent global patent database, Espacenet, and linguistically accessible for innovators
Office. Our from both regions using a single tool, Patent Translate. Under the new
experienced and arrangement with SIPO, Espacenet has grown by 4 million Chinese language
technically trained
Read More>> Go to the top>>
professionals do a
comprehensive
understanding of the Global IP Filings Continue to Grow, China Tops Global Patent
subject matter and use Filings
their exceptional
communication skills A new WIPO report shows that while the global economy continued to
underperform, intellectual property (IP) filings worldwide kept growing
to elucidate the
strongly in 2011. It also finds that China’s patent office became the largest in
invention and the draft
the world, as measured by the number of patent applications received. Before
is by default reviewed 2011, China already accounted for most filings of utility models (UMs),
by an Indian Patent trademarks and industrial designs.
Attorney. Further, the World Intellectual Property Indicators 2012 shows that patent filings
draft is reviewed by worldwide grew by 7.8% in 2011, exceeding 7% growth for the second year
respective filing in a row. Similarly, UM, industrial design and trademark filings increased by
country Patent 35%, 16% and 13.3%, respectively.
Attorney.
Read More>> Go to the top>>
We have Illustrators
who are well
conversant with the East Asia faces unique challenges, opportunities for stem cell
rules of USPTO, PCT innovation
and other National Tension is the theme running through the new consensus statement
Patent Offices. issued by the Hinxton Group, an international working group on stem cell
research and regulation. Specifically, tension between intellectual property
policies and scientific norms of free exchange, but also between eastern and
Page 6 of 13
© TT Consultants, 2013. All rights reserved – privileged and confidential

9. NEWS CHINA
western cultures, national and international interests, and privatized vs.
nationalized health care systems. The consensus, titled Statement on Data and
Materials Sharing and Intellectual Property in Pluripotent Stem Cell Science
in Japan and China, was released on the Hinxton Group's website on
November 19, 2012.
Patent & Trademark "China and Japan are among the world's leading nations in stem cell research,
Filing in India but because of challenges distinct from western nations, they are dramatically
underrepresented in terms of patents and licensing,"
Our Indian IP
Read More>> Go to the top>>
Prosecution Partner –
Talwar Advocates
established since 1983, China’s new approach to renewable energy
handles patent and Chinese companies are using innovative business models to change the
trademark filing in the cost structures and capabilities
Indian Patent Offices. involved in delivering renewable
The firm has the energy technology. Through strategic
infrastructure and partnerships with technology-led
resources to take on companies in the US and Europe, they
the whole range of are rapidly reducing the cost of
conventional and non- production and effectively entering the
conventional IP issues value-added parts of the global
technology economy.
and offer clients
In the popular imagination, China’s industrial base is largely built on
comprehensive
agriculture and manufacturing. This is still generally true. Agriculture
services in structuring
employs an enormous proportion of the workforce and vast lands are
and securing a patent dedicated to the painstaking process of growing rice or harvesting wheat.
portfolio. The firm
possesses the distinct Read More>> Go to the top>>
advantage of filing
Patents, Trademarks
Light at the end of the tunnel: trademark squatting in China
and PCT National
Trademark squatting has been a nightmare for many overseas
Phase applications
trademark owners for a long time, and more so in recent years. Our partner,
electronically in Indian Kenny Wong, published an article last month in Intellectual Property
Patent Office. Magazine, titled "Kung fu trademark hustle", in which he says there are
encouraging signs that we may be seeing light at the end of the tunnel.
Following the Trademark Office, the Chinese judiciary has also openly
acknowledged the problem. On December 3, the Beijing No. 1 Intermediate
People's Court held a press conference to report on their study into "the cause,
Page 7 of 13
© TT Consultants, 2013. All rights reserved – privileged and confidential

10. NEWS CHINA
characteristic and judicial response to trademark squatting". Vice president
Chen Rui, a supervisor of intellectual property cases at the intermediate court
Claim Chart and the leader of the task force, said that the courts should fully exert their
Preparation judicial function by aiming to deter squatting activities when they interpret
and apply the law.
This search helps in
Utah Hosts China-U.S.
Read More>> Go to the top>>
Intellectual the potential
identifying Property
Rights Roundtable
infringers of a particular
China Officially Recognizes Napa Valley Wines
BSA: Global software
patent portfolio. Over
theft totaled $63.4 billion For more than a decade, Napa Valley vintners have been exporting
the years, we have
last year wine to China; and now, one of the most recognizable wine regions in the
evolved an innovative world will be the first acknowledged with Geographic Indication (GI) status in
Court finds copyright of China. Geographical indications are used in all countries to act as a
Buddha designstrategy to
and effective valid
certification of authenticity. This is the first time that China has granted a GI
identify infringing recognition to any wine region outside of its own borders.
TechFaith Sues Samsung
products/standards and
for Patent Infringement “Being first speaks volumes to what people think about Napa Valley,”
ascertaining the said Terry Hall of the Napa Valley Vintners. The Napa Valley Vintners
In Search of 'Dexter':
brokered the deal, working with the Chinese government for nearly 14 years.
Why You Can't Buy This
infringement.
The new GI status step will help prevent Napa Valley knockoffs and
Pirated DVDs in China a
service is used by counterfeiting of labels and allow for consumer protection in China's rapidly
Anymore growing market.
leading semiconductor
manufacturer and some Read More>> Go to the top>>
fortune 500 companies
across the globe.
Page 8 of 13
© TT Consultants, 2013. All rights reserved – privileged and confidential

11. NEWS JAPAN
Japan, China pay a high price
Confirmation of the costly economic consequences of the continuing spat
Patent Watch between Japan and China over who owns a tiny string of remote uninhabited
rocky islets in the East China Sea came with the publication of Japan's
The patent alert service is September trade figures. They showed an unprecedented deficit of $7 billion
for clients who wish to as exports dropped by 10.3 percent, thanks to the global slowdown and to
remain updated about the Beijing's determination to teach Tokyo a lesson.
latest patents filed in their
Can China and Japan really be contemplating the madness of going to war
preferred field of invention.
over who owns this small real estate? Two months ago, most commentators
It is a practical step taken by
expressed confidence that the row would soon blow over, but it is continuing
most of the companies who
with new bellicose words, provocative actions and political tensions between
desire to keep track of the the once and future economic powers. New leaders settling in in Beijing dare
new and improved not risk being seen as weak, and Tokyo's nationalists will keep up the
formulations and adjuvant pressure. When and how will it end?
relating to their field of
Read More>> Go to the top>>
interest or in respect to a
competitor's patents.
Accordingly, we endeavor Japan gives patent for Medgenics IFNa pump
to observe patents Medgenics received a Notice of Allowance from the Japanese Patent
continually and provide and Trademark Office for key claims protecting the use of Medgenics'
regular updates to our Infradure Biopump technology for the delivery of interferon alpha (IFNa).
clients. Further, our search Medgenics is developing Infradure as a new approach to provide sustained
includes online product and patient compliant interferon therapy to address unmet needs in the
directory and other non treatment of hepatitis B, C, and D.
patent literature available. Similar claims protecting Medgenics' Infradure technology have been
granted or allowed in other large Asian markets including, China, Korea and
Australia. In addition, these countries have allowed broad claims to
Medgenics protecting the core Biopump technology for production and
delivery of proteins. Patents covering core Biopump technology for a
genetically modified dermal micro-organ have already been granted to
Medgenics in the US and in the EU.
Read More>> Go to the top>>
Astellas-UCB rheumatoid arthritis therapy wins marketing
approval in Japan
Astellas Pharma and UCB have announced the marketing approval of Cimzia
(certolizumab pegol) to treat rheumatoid arthritis (RA) in Japan. The
Page 9 of 13
© TT Consultants, 2013. All rights reserved – privileged and confidential

12. NEWS JAPAN
Japanese Ministry of Health, Labor and Welfare has approved Cimzia as a
200mg syringe for subcutaneous (s.c.) injection to treat adult RA patients who
failed to respond to conventional treatment.
Patent Landscape The only PEGylated Fc-free anti-TNF is designed in the form of a prefilled
Analysis syringe that enables self-administration by RA patients. Adult patients can be
administered with 400mg s.c. of certolizumab pegol at weeks zero, two and
With the help of our four, subsequent to 200mg every two weeks, while 400mg every four weeks
technical experts, s.c. can be considered for maintenance dosing.
experienced patent
searchers and IP tools Read More>> Go to the top>>
developed in-house, we
have been able to Bristol-Myers, Pfizer win approval for Eliquis in Japan
provide valuable Bristol-Myers Squibb and Pfizer have announced the approval of
reports to our clients. Eliquis (apixaban) anticoagulant for the prevention of ischemic stroke and
Our reports have systemic embolism in patients suffering from nonvalvular atrial fibrillation
enabled several (NVAF) in Japan.
technology companies
The Japanese approval of the anticoagulant is based on ARISTOTLE,
across the world to
the pivotal Phase 3 trial conducted in 18,201 NVAF patients, which assessed
take important strategic the safety and efficacy of ELIQUIS compared to warfarin.
decisions. We have
performed patent A subanalysis of the ARISTOTLE study also established a similar
landscape studies for safety and efficacy profile of ELIQUIS in Japanese patients, compared to the
one of the leading overall study. Bristol-Myers Squibb intercontinental region and Japan
semiconductor executive vice president and chief financial officer Charles Bancroft said,
"Today's approval of ELIQUIS is the result of our shared vision with Pfizer to
companies in the US
introduce a differentiated treatment option to reduce the burden of stroke in
and a top LED
patients with nonvalvular atrial fibrillation."
manufacturer of Asia
to name a few. Read More>> Go to the top>>
Novartis future growth prospects secured by industry-leading
pipeline
Novartis has provided an update on its leading Research and
Development (R&D) pipeline and plans for turning these assets into
commercial success to provide the basis for continued growth of the Group
through 2017. Continuing R&D productivity in the Pharmaceuticals Division
has fueled an industry-leading pipeline with 139 projects in clinical
development with more than 73 New Molecular Entities (NMEs) across a
multitude of disease areas. Highlights include RLX030 and LCZ696 in heart
Page 10 of 13
© TT Consultants, 2013. All rights reserved – privileged and confidential

13. NEWS JAPAN
failure as well as AIN457 in psoriasis and multiple sclerosis. In addition, the
company will showcase a comprehensive early and late-stage pipeline of
novel oncology compounds. "As a science-driven company, Novartis is
focused on innovation to address unmet medical needs for patients around the
world." said Joseph Jimenez, CEO of Novartis.
Read More>> Go to the top>>
Whitespace Analysis
Roche reports positive studies of MabThera given by
Our White Space subcutaneous injection
analysis study comes Pivotal study data presented at ASH shows that subcutaneous
in handy if you are administration enables the delivery of MabThera over approximately 5
looking at the future minutes without compromising MabThera’s proven efficacy and safety
of a new technology
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results
or looking to diversify
from two studies which showed that a fixed dose of MabThera (rituximab) can
into new avenues of be administered subcutaneously (SC), potentially allowing patients to spend
technology. We less time in infusion centers receiving their MabThera treatment. Specifically,
compile and study the studies showed that SC injection resulted in non-inferior MabThera
variety of literature concentrations in the blood (pharmacokinetics; PK) compared with standard
available for a intravenous (IV) infusion. Overall, SC and IV adverse event (AE) profiles
technology- filing were similar and administration related reactions (ARR) were mostly of mild
trends add up to our to moderate intensity.
analysis and we Read More>> Go to the top>>
provide
recommendations Govt to Mandate Price Cuts On Popular Off-Patent Drugs
and an idea of the Off-patent name-brand drugs with continued high market shares will
road ahead. face steep price cuts under a new rule to be introduced as soon as 2014 in an
initiative to curb health care costs. Off-patent drugs typically lose market
share to their cheaper generic counterparts. But in Japan, they tend to maintain
a high share even after their patents expire, primarily due to the
manufacturer's brand strength and stable supplies. As a result, generic
products account for less than 30% of the Japanese drug market.
The new rule, endorsed Wednesday by a Health Ministry panel, will
slash the prices of post-patent drugs if consumers are slow to shift to the
generic equivalent. Details, such as the timing of the price cuts, will be
discussed starting next year, with plans to implement the change as early as
April 1, 2014.
Read More>> Go to the top>>
Page 11 of 13
© TT Consultants, 2013. All rights reserved – privileged and confidential

14. EDITORIAL
The prime solution - Invalidation search
Technology Transfer/ A shrinking global economy and rapid growth in emerging countries,
infringement analysis has poised to become an essential tool for companies.
Commercialization
Patent troll, another concept which has emerged over the years, has further
TT Consultants is contributed in the rise of infringement cases.
“According to the U.S. Department of Commerce, there has been a
working with several
76% increase in claims for trademark and patent infringement in the past
technology companies 10 years.”
on patent licensing,
The prime solution - Invalidation search.
technology/product Conducting a prior art search could be a daunting task for most people.
commercialization, and Only an experienced searcher equipped with professional tools and access to
appropriate databases can perform a search to an adequate degree.
know-how transfer. We
With 2000+ invalidation searches to its credit, TT Consultants
have: distinguishes itself with innovative and detailed methodology. We 'scour the
earth' when it comes to searching for prior art in order to invalidate a
 Established India troublesome patent. The non-exhaustive patent and non-patent databases
employed by the companies include Questel Orbit, TI, Total Patents
Business Desk for
LexisNexis, KIPRIS, TIPO, CIPO, AUSPAT, Espacenet, PAJ, SIPO, IEEE,
the incubation IP.com, Science Direct, Springer, Pubmed, NCBI, Scirus and many others.
companies of several TT Consultants, with plenty of competitive IP services offering, has
prior art searching leading the portfolio of the company. The company has
national universities gained victory by invalidation several potentially dangerous patents, helping
of Taiwan companies coming out of Patent Trolls and thus, saving millions of dollars.
 Tie-ups with the best Invalidation Search at TT Consultants
research institutes in  Multilingual Searching: Through our East Asia presence in Taiwan, we
have in-house Native Searchers from all technical backgrounds and
Asia
further, tie-ups with several native searchers/firms through which we
 Successfully provide Chinese (Traditional and Non Traditional), Taiwan, Japanese,
commercialized French and German search capabilities.
 Detailed Methodology: We have a detailed list of SOPs that we adopt
several products and while conducting an invalidation search. Some of the brief SOPs include
technologies in understanding of the subject patent, file wrapper review, patent webbing,
inequitable conduct search, keyword and classification based search,
various parts of the
combinational search, citation analysis, inventor/assignee search, Native
world. search and thorough Non-patent search. The project managers crosscheck
the report quality and adherence to SOPs during the search. Further, the
identified prior art references are verified (technical relevancy and other
limitations such as date criteria, assignee, etc.) by the project manager
Page 12 of 13
© TT Consultants, 2013. All rights reserved – privileged and confidential

15. EDITORIAL
before mapping it into the report.
 Inequitable conduct search: We offer Inequitable Conduct Search by
Patent Acquisition default in all invalidation projects. Using sophisticated and innovative
Services databases, we uncover priceless patents that were not reported to the one
Patent Acquisition/ In- or the other patent office but were cited during prosecution in other
countries and this can lead to an excellent settlement in your favor.
Licensing
 Quick Turnaround: TT Consultants has been successful on several
We work closely with our
occasions by providing search results in a very short span of time.
clients for acquiring the
Normally, the turnaround time for our invalidation search is 6 working
right patents at the right days but if you are looking at a weekend turnaround, that’s achievable.
value. The support ranges  Reports on Rolling Basis: The Company provides the additional facility
from landscape, evaluating for the client to receive the identified prior art as they are identified. This
patent strength to gauging lets the client to better analyze the probability of finding the most relevant
enforcement value. prior arts.
 Additional Analysis: An additional analysis is a complete analysis of all
Patent Out-Licensing
the patents and prior arts studied during the search. The trends and pattern
We help our clients to for filing and publication activity of various active assignees and inventors
license their patents to the are studied for the technology domain. This analysis is represented as
right purchasers for the graphs and charts making the data easy to analyze.
right value. This includes  No Stone Unturned search: A “No Stone Unturned Search” is an
identifying the right extended invalidation search conducted by a team of 4 resources for the
buyers, performing duration of four weeks which can be further expedited based on the
infringement analysis and client’s requirement. Further, native searches are performed as and when
other important aspects. required. This gives a broad coverage to any relevant prior arts that may
exist.
Go to the top>>
Page 13 of 13
© TT Consultants, 2013. All rights reserved – privileged and confidential

16. INDIA WASHINGTON DC TAIWAN
Chandigarh TT Consultants LLC Tainan (Branch Office)
Office 8, Tower B, 3rd Floor, D.L.F, I.T park 1701, Pennsylvania Avenue, NW, Room 410, Technology Transfer & Business
Chandigarh (U.T)-160101, India Washington DC. 20006 Incubation Center,
Mobile: +91-9815006413 Mobile: +1.347.284.6413 National Cheng Kung University,
Email: s.goel@ttconsultants.co.in Toll Free: +1.888.337.5234 No. 1 University Road, Tainan City 701
Gurgaon Email: talwar@ttconsultants.co.in
Unit number 252, 2nd floor, Tower B2, Hsinchu
Si-Soft Research Center, 1A2,
Spaze I-Tech Park, Sector 49,
Lising 1st Road, Hsinchu City
Sohna Road, Gurgaon-122002 Landline: +886-6-2368814
Mobile: +91-9876196354
Email: n.mahajan@ttconsultants.co.in Email: a.srivastava@ttconsultants.co.in
Subscribe/Opt in
If you wish to receive this Newsletter in future, please click here.
Feedback/Suggestion
We will be happy to know your feedback & suggestion on the same. Kindly send us an email with your feedback.
Unsubscribe
If you do not wish to receive this Newsletter in future, please click here, else just reply this mail with the word "Unsubscribe" in the
subject of the mail.
Disclaimer
While every care has been taken in the preparation of this News Bulletin to ensure its accuracy at the time of publication, TT
Consultants assumes no responsibility for any errors which despite all precautions, may be found herein. Neither this bulletin nor the
information contained herein constitutes a contract or will form the basis of a contract. The material contained in this document does
not constitute/substitute professional advice that maybe required before acting on any matter.
*COPYRIGHT NOTICE:-© 2013, India. All Rights reserved with TT Consultants
Go To Top >>
© TT Consultants, 2013. All rights reserved – privileged and confidential